July 28, 2017 10:57 AM EDTUpdated 11:32 AM
News Briefing

Idor­sia touts new sleep drug da­ta ahead of PhI­II; Tetraphase out to raise $65M

Shehla Shakoor

Managing Director

→ Acte­lion spin­out Idor­sia says it scored pos­i­tive da­ta from two Phase II stud­ies of a new sleep drug called ACT-541468. In­ves­ti­ga­tors say that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times